Colin Hislop

1.3k total citations
17 papers, 484 citations indexed

About

Colin Hislop is a scholar working on Surgery, Cancer Research and Molecular Biology. According to data from OpenAlex, Colin Hislop has authored 17 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 7 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Colin Hislop's work include Lipoproteins and Cardiovascular Health (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Protease and Inhibitor Mechanisms (5 papers). Colin Hislop is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Protease and Inhibitor Mechanisms (5 papers). Colin Hislop collaborates with scholars based in United States, United Kingdom and Brazil. Colin Hislop's co-authors include Robert S. Rosenson, David D. Waters, Michael D. Elliott, Yuri Stasiv, Renée S. Martin, Morton Scheinberg, Alvina D. Chu, G. Léon, Michelle Petri and Richard Furie and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Colin Hislop

17 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Colin Hislop United States 9 185 181 143 136 118 17 484
José Osorio France 6 141 0.8× 172 1.0× 188 1.3× 183 1.3× 80 0.7× 7 487
Ashley J. Wilhelm United States 11 313 1.7× 148 0.8× 157 1.1× 141 1.0× 15 0.1× 13 511
Erika Polz Austria 7 101 0.5× 153 0.8× 62 0.4× 195 1.4× 113 1.0× 8 469
Š Rùzicková Czechia 11 203 1.1× 168 0.9× 41 0.3× 110 0.8× 42 0.4× 20 463
K Norioka Japan 15 200 1.1× 121 0.7× 76 0.5× 108 0.8× 56 0.5× 28 461
Sara Rufini Italy 10 116 0.6× 164 0.9× 24 0.2× 139 1.0× 37 0.3× 16 424
Kayaho Maeda Japan 13 410 2.2× 224 1.2× 47 0.3× 182 1.3× 26 0.2× 29 692
Arnon Arazi United States 9 178 1.0× 109 0.6× 128 0.9× 103 0.8× 24 0.2× 14 472
Kirsty E. Waddington United Kingdom 13 186 1.0× 263 1.5× 96 0.7× 108 0.8× 13 0.1× 20 505
Daniel Torres‐Moreno Spain 12 97 0.5× 114 0.6× 41 0.3× 64 0.5× 23 0.2× 24 399

Countries citing papers authored by Colin Hislop

Since Specialization
Citations

This map shows the geographic impact of Colin Hislop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Hislop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Hislop more than expected).

Fields of papers citing papers by Colin Hislop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Hislop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Hislop. The network helps show where Colin Hislop may publish in the future.

Co-authorship network of co-authors of Colin Hislop

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Hislop. A scholar is included among the top collaborators of Colin Hislop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Hislop. Colin Hislop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Scheinberg, Morton, Colin Hislop, & Renée S. Martin. (2016). Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opinion on Biological Therapy. 16(5). 723–733. 10 indexed citations
2.
3.
4.
Furie, Richard, G. Léon, Michelle Petri, et al.. (2014). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Annals of the Rheumatic Diseases. 74(9). 1667–1675. 127 indexed citations
5.
Richard, Florence, Morton Scheinberg, Alvina D. Chu, et al.. (2014). FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies. Annals of the Rheumatic Diseases. 73. 527–528. 1 indexed citations
6.
Furie, R., Morton Scheinberg, G. Léon, et al.. (2013). OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE. Annals of the Rheumatic Diseases. 72. A90–A91. 4 indexed citations
7.
Furie, Richard, Morton Scheinberg, G. Léon, et al.. (2013). OP0129 Effects of Blisibimod, an Inhibitor of B-Cell Activating Factor, on Markers of Renal Disease in Patients with SLE. Annals of the Rheumatic Diseases. 72. A95–A95. 2 indexed citations
8.
Rosenson, Robert S., Heather Fraser, Michael A. Goulder, & Colin Hislop. (2011). Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy. 25(6). 539–544. 15 indexed citations
9.
Nicholls, Stephen J., Matthew A. Cavender, John J.P. Kastelein, et al.. (2011). Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial. Cardiovascular Drugs and Therapy. 26(1). 71–75. 37 indexed citations
10.
Rosenson, Robert S. & Colin Hislop. (2010). EFFECTS OF VARESPLADIB METHYL ON BIOMARKERS AND MAJOR CARDIOVASCULAR EVENTS IN ACUTE CORONARY SYNDROME PATIENTS. Journal of the American College of Cardiology. 55(10). A114.E1063–A114.E1063. 3 indexed citations
11.
Rosenson, Robert S., Colin Hislop, Michael D. Elliott, et al.. (2010). Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients. Journal of the American College of Cardiology. 56(14). 1079–1088. 69 indexed citations
12.
Rosenson, Robert S., Heather Fraser, Joaquim Trias, & Colin Hislop. (2010). Varespladib methyl in cardiovascular disease. Expert Opinion on Investigational Drugs. 19(10). 1245–1255. 12 indexed citations
13.
Rosenson, Robert S., Michael D. Elliott, Yuri Stasiv, et al.. (2010). Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. European Heart Journal. 32(8). 999–1005. 40 indexed citations
14.
Rosenson, Robert S., Colin Hislop, Daniel McConnell, et al.. (2009). Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. The Lancet. 373(9664). 649–658. 86 indexed citations
15.
Fraser, Heather, Colin Hislop, Robert Christie, et al.. (2009). Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − Mice. Journal of Cardiovascular Pharmacology. 53(1). 60–65. 70 indexed citations
16.
Rosenson, Robert S., Colin Hislop, Michael D. Elliott, & Yuri Stasiv. (2008). Abstract 1928: Effects of a Selective Inhibitor of Secretory Phospholipase A2 on Low Density and Very Low Density Lipoprotein Subclasses in Stable Coronary Heart Disease Patients. Circulation. 118. 2 indexed citations
17.
Hislop, Colin. (1997). Leg ulcer assessment by doppler ultrasound. Nursing Standard. 11(43). 49–56. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Osorio Breakdown of academic impact, for papers by Ashley J. Wilhelm Breakdown of academic impact, for papers by Erika Polz Breakdown of academic impact, for papers by Š Rùzicková Breakdown of academic impact, for papers by K Norioka Breakdown of academic impact, for papers by Sara Rufini Breakdown of academic impact, for papers by Kayaho Maeda Breakdown of academic impact, for papers by Arnon Arazi Breakdown of academic impact, for papers by Kirsty E. Waddington Breakdown of academic impact, for papers by Daniel Torres‐Moreno
Rankless by CCL
2026